0001171843-23-001588.txt : 20230310
0001171843-23-001588.hdr.sgml : 20230310
20230310133451
ACCESSION NUMBER: 0001171843-23-001588
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230310
FILED AS OF DATE: 20230310
DATE AS OF CHANGE: 20230310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schuetz Thomas J.
CENTRAL INDEX KEY: 0001591464
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39696
FILM NUMBER: 23722942
MAIL ADDRESS:
STREET 1: C/O RELYPSA, INC.
STREET 2: 700 SAGINAW DR.
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Compass Therapeutics, Inc.
CENTRAL INDEX KEY: 0001738021
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
BUSINESS PHONE: 617-500-8099
MAIL ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
FORMER COMPANY:
FORMER CONFORMED NAME: Olivia Ventures, Inc.
DATE OF NAME CHANGE: 20180419
4
1
ownership.xml
X0306
4
2023-03-10
0
0001738021
Compass Therapeutics, Inc.
CMPX
0001591464
Schuetz Thomas J.
C/O COMPASS THERAPEUTICS, INC.
80 GUEST ST., SUITE 601
BOSTON
MA
02135
1
1
0
0
CHIEF EXECUTIVE OFFICER
Common Stock
2023-03-10
4
P
0
10000
3.37
A
6021873
D
The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.30 to $3.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.
89,051 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 27,937 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 61,114 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022.
/s/ Thomas J. Schuetz
2023-03-10